Addex Therapeutics (FRA:APE1) Research & Development: €0.18 Mil (TTM As of Mar. 2026)


FRA:APE1 Addex Therapeutics Ltd FRA:APE1
7 GF Score
Price €4.90
GF Value €1.12
! 6 Warning Signs
View Full Analysis

What is Addex Therapeutics Research & Development?

Addex Therapeutics FRA:APE1 -3.92% 7 Research & Development is €0.18 Mil as of Mar. 2026. GuruFocus rates FRA:APE1 with a GF Score™ of 7/100 and a GF Value™ of €1.12. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Addex Therapeutics's Research & Development for the three months ended in Mar. 2026 was €0.01 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.18 Mil.

Addex Therapeutics  (FRA:APE1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Addex Therapeutics Research & Development Related Terms

Addex Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics Research & Development Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.66 7.99 1.00 0.47 0.20

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.07 0.09 0.00 0.01
FRA:APE1
7GF Score
Addex Therapeutics Ltd FRA:APE1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Addex Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.18 Mil mean?
Addex Therapeutics (FRA:APE1) has a Research & Development of €0.18 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Addex Therapeutics and its competitors.
Is Addex Therapeutics' Research & Development too high?
Addex Therapeutics' current Research & Development is €0.18 Mil. Overall, Addex Therapeutics has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Addex Therapeutics' Research & Development compare to VRTX and REGN?
Addex Therapeutics' Research & Development of €0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current Research & Development is €0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE1) has a current Research & Development of €0.18 Mil. The stock's GF Value™ is €1.12, compared to a current price of €4.90 — trading 337.5% above its estimated fair value. The current Research & Development is €0.18 Mil. Addex Therapeutics' overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE1), the current Research & Development is €0.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Addex Therapeutics (FRA:APE1) Overvalued in 2026?

Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued. The current stock price of €4.90 is trading 337.5% above its estimated GF Value™ of €1.12.

Key valuation signals for FRA:APE1:

  • Research & Development: €0.18 Mil
  • GF Value™: €1.12 vs. price of €4.90 (337.5% above fair value)
  • GF Score™: 7/100 with 6 warning signs

No single metric tells the full story. See the FRA:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score

Get the complete analysis for FRA:APE1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.90
Price
€1.12
GF Value